Capital Fund Management S.A. Takes $2.73 Million Position in Maximus, Inc. $MMS

Key Points

• Capital Fund Management S.A. purchased 40,005 shares of Maximus, Inc. valued at approximately $2.73 million during the first quarter, holding about 0.07% of the company.
• Director Gayathri Rajan sold 7,913 shares of Maximus, reducing her position by 35.78%, with the sale totaling $572,742.94.
• Wall Street Zen recently downgraded Maximus from a "buy" to a "hold" rating, while the stock currently maintains an average target price of $90.00 according to analyst estimates.

Capital Fund Management S.A. acquired a new stake in shares of Maximus, Inc. (NYSE:MMS - Free Report) in the 1st quarter, according to its most recent 13F filing with the SEC. The fund acquired 40,005 shares of the health services provider's stock, valued at approximately $2,728,000. Capital Fund Management S.A. owned 0.07% of Maximus at the end of the most recent quarter.

Several other large investors have also made changes to their positions in MMS. Raymond James Financial Inc. purchased a new position in shares of Maximus during the fourth quarter worth $1,169,000. Mariner LLC raised its stake in shares of Maximus by 15.7% during the 4th quarter. Mariner LLC now owns 5,864 shares of the health services provider's stock valued at $438,000 after buying an additional 795 shares during the last quarter. Dimensional Fund Advisors LP raised its position in Maximus by 14.4% during the fourth quarter. Dimensional Fund Advisors LP now owns 1,406,592 shares of the health services provider's stock valued at $105,001,000 after acquiring an additional 177,075 shares in the last quarter. Tower Research Capital LLC TRC lifted its stake in shares of Maximus by 153.0% in the 4th quarter. Tower Research Capital LLC TRC now owns 6,296 shares of the health services provider's stock valued at $470,000 after purchasing an additional 3,807 shares during the period. Finally, Price T Rowe Associates Inc. MD boosted its stake in shares of Maximus by 9.5% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 44,478 shares of the health services provider's stock worth $3,321,000 after acquiring an additional 3,842 shares in the last quarter. 97.21% of the stock is owned by hedge funds and other institutional investors.

Maximus Stock Performance

NYSE MMS traded up $0.34 on Friday, reaching $88.06. The stock had a trading volume of 434,573 shares, compared to its average volume of 681,324. The stock has a market cap of $4.96 billion, a P/E ratio of 16.22 and a beta of 0.60. The business's 50-day moving average price is $76.35 and its 200 day moving average price is $71.67. The company has a debt-to-equity ratio of 0.91, a quick ratio of 2.27 and a current ratio of 2.27. Maximus, Inc. has a 12-month low of $63.77 and a 12-month high of $93.94.

Maximus (NYSE:MMS - Get Free Report) last announced its earnings results on Thursday, August 7th. The health services provider reported $2.16 earnings per share for the quarter, beating the consensus estimate of $1.39 by $0.77. Maximus had a return on equity of 24.44% and a net margin of 5.83%.The company had revenue of $1.35 billion for the quarter, compared to the consensus estimate of $1.29 billion. During the same period last year, the business posted $1.74 EPS. The company's revenue was up 2.5% on a year-over-year basis. Maximus has set its FY 2025 guidance at 7.350-7.550 EPS. As a group, equities analysts expect that Maximus, Inc. will post 6.15 earnings per share for the current year.

Maximus Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Sunday, August 31st. Investors of record on Friday, August 15th will be paid a $0.30 dividend. The ex-dividend date is Friday, August 15th. This represents a $1.20 annualized dividend and a dividend yield of 1.4%. Maximus's dividend payout ratio (DPR) is 22.10%.

Analysts Set New Price Targets

MMS has been the subject of several recent analyst reports. Wall Street Zen lowered shares of Maximus from a "buy" rating to a "hold" rating in a report on Thursday, May 15th. Zacks Research upgraded Maximus from a "hold" rating to a "strong-buy" rating in a research report on Tuesday. One investment analyst has rated the stock with a Strong Buy rating and one has assigned a Buy rating to the company's stock. According to data from MarketBeat, the company presently has a consensus rating of "Strong Buy" and a consensus target price of $90.00.

About Maximus

Maximus, Inc operates as a provider of government services in the United States and internationally. It operates through three segments: U.S. Federal Services, U.S. Services, and Outside the U.S. The U.S. Services segment offers program eligibility support and enrollment; centralized multilingual customer contact centers, multichannel, and digital self-service options for enrollment; application assistance and independent health plan choice counseling; beneficiary outreach, education, eligibility, enrollment, and redeterminations; and person-centered independent disability, long-term sick, and other health assessments.